U.S. Food and Drug Administration accepts the submitted Biologic License Application for Coagulation Factor VIIa (Recombinant), activated eptacog beta.
Healthcare professionals, learn more about the science behind HEMA Biologics investigational therapies for the treatment of rare bleeding disorders.
Check out our new app, and become Sergeant Factor in this exciting interactive experience.
“Our mission is to help improve health and care for people living with
the rarest bleeding disorders.”
Copyright ©2017|HEMA Biologics|All rights Reserved.